MiscellaneousBIOVERSYS SUCCESSFULLY ADVANCES BV500 NTM PROGRAM WITH CONTINUED SUPPORT FROM CF AMR SYNDICATE 11.02.2025 / 07:00 CET/CESTBasel, Switzerland. February 11, 2025, 7am CET BV500 reaches ...
Allison John and Rocky When Allison John was 13 and watching the science programme Tomorrow’s World , a segment on gene therapy came up. This was cutting edge stuff in the early 1990s and John had ...
The US Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for brensocatib for patients with ...
JASPER: My name is Jasper and I have Cystic fibrosis. Cystic fibrosis is an invisible ... Discuss these suggestions as a class and ask how they could apply them to other situations as well.
Insmed (INSM) announced that the U.S. FDA has accepted the company’s New Drug Application for brensocatib for patients with non-cystic fibrosis ...
Background Early-life inflammation has long been recognised as a key pathophysiological process in the evolution of cystic ...
Operator Good day, and welcome to the Vertex Pharmaceuticals fourth quarter 2024 earnings call. All participants will be in a ...
Insmed's promising drug pipeline includes Brensocatib and Arikayce. See why INSM stock is a strong pick with multi-billion ...
BRIDGEWATER, N.J. - Insmed Incorporated (NASDAQ:INSM), a biopharmaceutical company with a market capitalization of $14.57 ...
Two sizable companies and a handful of small Asian issuers were listed in the US this past week. Read more here.
Archie Manning writes: "As I go from place to place in Mississippi both in my travels and in my mind’s eye, I realize what I ...
The Tennessee chapter of the Cystic Fibrosis Foundation is accepting nominations ... driving Nashville’s growth… Celebrate the 2025 class of Women of Influence, a distinguished group of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback